Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia
article
OA: closed
CC0
⤵ 60 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This study investigated how treatment with the dopamine agonist quinagolide affects endometriotic lesions in patients experiencing hyperprolactinemia alongside endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (42)
- Advances in Treatment Options of Endometriosis via openalex
- Antiangiogenesis Therapy for Endometriosis via openalex
- Concentrations of Interferon‐γ‐Induced Protein‐10 (IP‐10), an Antiangiogenic Substance, are Decreased in Peritoneal Fluid of Women with Advanced Endometriosis via openalex
- Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis via openalex
- Emerging drugs in endometriosis via openalex
- Gene Expression Profiling of the Rat Endometriosis Model via openalex
- Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. via openalex
- Impact of gestrinone on the course of asymptomatic endometriosis. via openalex
- Laparoscopic evaluation of the onset and progression of endometriosis via openalex
- Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis via openalex
- Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. via openalex
- Rectal endometriosis and prolactinoma via openalex
- Role of cytokines in the endometrial-peritoneal cross-talk and development of endometriosis via openalex
- Simvastatin Protects against the Development of Endometriosis in a Nude Mouse Model via openalex
- The peritoneal environment in endometriosis via openalex
- Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. via openalex
- W2058731555 via openalex
- W2067201007 via openalex
- W2085215264 via openalex
- W2121594719 via openalex
- W2127881315 via openalex
- W2139944110 via openalex
- W2140392535 via openalex
- W2162891639 via openalex
- W2282638860 via openalex
- W6601444936 via openalex
- W6655318352 via openalex
- W164119867 via openalex
- W1549834656 via openalex
- W1965258805 via openalex
- W1974289191 via openalex
- W1978085719 via openalex
- W1979270155 via openalex
- W1989815049 via openalex
- W1989947339 via openalex
- W1991594161 via openalex
- W2023097658 via openalex
- W2025792694 via openalex
- W2028031291 via openalex
- W2033705087 via openalex
- W2040329362 via openalex
- W2049486103 via openalex
Cited by (50)
- Pathological roles of prolactin signaling in gynecologic and female-predominant diseases and prospects for targeted therapy 2026
- Complement and coagulation cascade cross-talk in endometriosis and the potential of JAK inhibitors – a network meta-analysis 2025
- Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors—a network meta-analysis 2025
- Novel targets for endometriosis-associated pain 2025
- Endometriosis: A Comprehensive and Concise Review of Potential Biomarkers and Treatment Therapies 2024
- Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis 2023
- Combined proteomics and transcriptomics identifies serpin family C member 1 associated protein as a biomarker of endometriosis 2023
- A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022 2023
- Medical Management of Ovarian Endometriomas 2023
- Prolactin and pain of endometriosis 2023
- Applying a computational transcriptomics-based drug repositioning pipeline to identify therapeutic candidates for endometriosis 2022
- Quinagolide Treatment Reduces Invasive and Angiogenic Properties of Endometrial Mesenchymal Stromal Cells 2022
- The Role of the Microenvironment in Endometriosis: Parallels and Distinctions to Cancer 2022
- Therapeutic Effect of Bromocriptine as a Dopamine Agonist on Endometrioma Size: A Double-Blind Randomized Controlled Trial 2022
- The effects of prolactin receptor blockade in a murine endometriosis interna model 2022
- Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis 2022
- Medical treatments of endometriosis: a review 2022
- The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma 2021
- The Effect of Novel Medical Nonhormonal Treatments on the Angiogenesis of Endometriotic Lesions 2021
- Pathogenesis of Endometriosis: New Insights into Prospective Therapies 2021
- Medical management of endometriosis 2021
- Role of medical treatment of endometriosis 2021
- A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment 2021
- Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review 2021
- Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate 2021
- Management of Endometriosis in Teenagers 2020
- Dopamine agonists as genital endometriosis target therapy 2020
- Use of dopamine agonists to target angiogenesis in women with endometriosis 2020
- The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 2020
- A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy 2019
- Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going? 2019
- Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies 2018
- Comparative assessment of effectiveness of new drugs for targeted therapy of endometriosis by experimental model 2018
- Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women 2018
- Current and emerging treatment options for endometriosis 2018
- Basic mechanisms of vascularization in endometriosis and their clinical implications 2018
- Evaluation of PAI-1 in endometriosis using a homologous immunocompetent mouse model† 2018
- Dysfunctional signaling underlying endometriosis: current state of knowledge 2018
- Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
- Comparative assessment of effectiveness of new drugs for targeted therapy of endometriosis by experimental model 2018
- KLFII is an Epigenetic Mediator of DRD2/Dopaminergic Signaling in Endometriosis 2017
- The Molecular Mechanistic Effects of Acupuncture in Endometriosis Management 2017
- A peek into the drug development scenario of endometriosis – A systematic review 2017
- Medical Management of Endometriosis 2017
- An Update on Pathophysiology and Medical Management of Endometriosis 2016
- The Non-Ergot Derived Dopamine Agonist Quinagolide as an Anti-Endometriotic Agent 2016
- The role of prolactin аnd dopamine in the pathogenesis of endometriosis 2016
- Emerging treatment of endometriosis 2015
- Challenges in the development of novel therapeutic strategies for treatment of endometriosis 2015
- An overview of early drug development for endometriosis 2015
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0
· commercial use OK